Atara Biotherapeutics (ATRA) Current Deferred Revenue (2020 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Current Deferred Revenue came in at $684000.0 in Q1 2026, down 95.72% YoY from $16.0 million in Q1 2025, and down 4.47% on a QoQ basis from $716000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 7 years of Current Deferred Revenue data on file, last reported at $684000.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 95.72% year-over-year to $684000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $684000.0 (down 95.72% YoY) and the FY2025 annual result came in at $716000.0, down 99.25% from the prior year.
- Current Deferred Revenue declined to $684000.0 in Q1 2026, from $716000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $123.2 million in Q1 2024 to a low of $684000.0 in Q1 2026.
- A 5-year average of $37.5 million and a median of $11.6 million in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue surged 1140.97% — and 2025, when it tumbled 99.25%.
- Tracing ATRA's Current Deferred Revenue over 5 years: stood at $8.0 million in 2022, then jumped by 872.91% to $77.8 million in 2023, then increased by 22.17% to $95.1 million in 2024, then plunged by 99.25% to $716000.0 in 2025, then declined by 4.47% to $684000.0 in 2026.
- The last three Current Deferred Revenue figures came in at $684000.0 (Q1 2026), $716000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 775,000.00 |
| Mar 31, 2026 | 684,000.00 |
| Dec 31, 2025 | 716,000.00 |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 15.98 Mn |
| Dec 31, 2024 | 95.09 Mn |
| Sep 30, 2024 | 116.34 Mn |
| Jun 30, 2024 | 107.58 Mn |
| Mar 31, 2024 | 123.15 Mn |
| Dec 31, 2023 | 77.83 Mn |
| Sep 30, 2023 | 11.61 Mn |
| Jun 30, 2023 | 11.95 Mn |
| Mar 31, 2023 | 9.92 Mn |
| Dec 31, 2022 | 8.00 Mn |
| Sep 30, 2022 | 2.66 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 50.94 Mn |
| Dec 31, 2021 | 40.76 Mn |
| Sep 30, 2021 | 31.23 Mn |